Medical News Feed
German Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
Want to submit or suggest content for the epgonline.org YouTube Clinical channel?
Contact us here
epgonline.org is not responsible for content on any 3rd party website
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
| Drug class description : | Alkylating agents (cytotoxics). |
| Generic Name : | Melphalan Glaxo Wellcome is discontinuing Alkeran 5mg tablets when existing stocks are exhausted. This is estimated to occur by the summer of 2001. |
| Drug description : | Alkeran tablets: 2mg white tablet coded A2A. 5 mg white tablet coded B2A. Both marked WELLCOME. Alkeran Injection: powder in ampoule plus diluent. |
| Presentation : | Alkeran Tablets: Melphalan 2 mg , 5mg . Alkeran Powder for Injection: Melphalan 50 mg . |
| Indications : | Alkeran Tablets: Indicated in the treatment of multiple myeloma and advanced ovarian adenocarcinoma. May also be used in the treatment of breast carcinoma (alone or in combination with other drugs or as adjuvant to surgery), polycythaemia rubra vera. Alkeran Injection: Indicated in the treatment of localised malignant melanoma of the extremities and localised soft tissue sarcoma of the extremities (administered by regional arterial perfusion). May also be used (alone or in conjunction with other drugs) to treat multiple myeloma, ovarian cancer, neuroblastoma in childhood. See Summary of Product Characteristics. |
| Adult Dosage : | Note: Alkeran should be prescribed only by physicians experienced in the management of malignant disease with alkylating agents. Dosage varies according to condition being treated. Refer to Summary of Product Characteristics. |
| Elderly Dosage : | Refer to Summary of Product Characteristics. Refer to Summary of Product Characteristics. |
| Contra Indications : | Previous hypersensitivity to melphalan. Lactation. |
| Special Precautions : | Note: Alkeran is an active cyctotoxic agent for use under the direction of physicians experienced in the administration of such agents. Alkeran injection - avoid extravasation as soft tissue damage may occur. High dose injection should only be administered at specialist centres. Monitor blood counts. Renal impairment. Pregnancy. See Summary of Product Characteristics. |
| Interactions : | Nalidixic acid, cyclosporin. |
| Adverse Reactions : | Bone marrow depression, GI effects, stomatitis, allergic reactions. Maculopaupular rashes, pruritus reported occasionally. See Summary of Product Characteristics. |
| Manufacturer : | GlaxoSmithKline(GSK) |
| Drug Availability : | (POM) |
Only registered users have access to the full EPG Online Knowledge Base including drug search tools, interactive disease Knowledge Centres via the EPG Knowledge Library - with clinical and evidence based physician and research tools, MiMedia (build your own clinical media collection with everything from key opinion leader essays to mode of action videos and other multi-media content), the EPG Survey panel, health news updates and much much more.
Already Registered?
Please log-in now using our member login box.
Not a member?
Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students.
Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major therapeutic areas, disease management, and clinical tools.
As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!
REGISTER today it only takes a minute! and it's FREE
Having problems?
Use our forgotten password facility or email us at: contact@epgonline.org